Anavar

Oxandrolone, sold under brand names such as Anavar and Oxandrin, is an orally active anabolic-androgenic steroid. It is structurally unusual among these drugs: it is a derivative of dihydrotestosterone in which one carbon of the steroid A-ring is replaced by an oxygen atom, making it a "2-oxa" steroid, and it carries a 17-alpha-methyl group that lets it survive oral dosing. These features give it strong anabolic activity relative to its androgenic activity ^[4].

The drug was first described in 1962 by researchers at Searle Laboratories and introduced for medical use in 1964 as Anavar. Production was discontinued for a period and then reintroduced in the mid-1990s under the name Oxandrin. It has been applied to a range of conditions requiring restoration of body weight and lean tissue.

Recognized medical uses include promoting weight gain after surgery, trauma, chronic infection, or prolonged corticosteroid therapy. Oxandrolone is well studied as an aid in the recovery of patients with severe burns; a systematic review of randomized trials reported that it shortened hospital stay and healing time and improved lean body mass without a clear increase in serious harm in that setting ^[1][3]. In girls with Turner syndrome treated with growth hormone, adding oxandrolone has been found to produce a modest gain in final adult height, at the cost of some virilizing effects such as voice deepening ^[2].

Because it is comparatively mild and available in oral form, oxandrolone is also used without prescription by athletes and bodybuilders, including women. Possible adverse effects include changes in blood lipids that may raise cardiovascular risk, suppression of natural testosterone, and, with higher or prolonged exposure, liver effects; although often considered less hepatotoxic than many 17-alpha-alkylated steroids, cases of liver injury have been reported.

Oxandrolone is a Schedule III controlled substance in the United States and is similarly scheduled in several other countries; it is banned in competitive sport. Its United States marketing approval was withdrawn in 2023, reflecting the availability of other treatments.

Anavar (oxandrolone) is a c17-alpha-alkylated oral steroid, so despite its mild reputation it carries dose-dependent hepatotoxicity and can raise liver enzymes and disturb liver function on prolonged use. Its most consistent documented harm is a sharp, unfavorable shift in lipids; it markedly suppresses HDL and raises LDL, straining cardiovascular health even at modest doses. It suppresses natural testosterone production (less severely than many steroids but enough to warrant recovery support after longer runs), and can cause virilization in women including voice deepening, clitoral enlargement, and hair changes that may be irreversible. Other reported effects include acne, mood changes, and reduced HDL-driven vascular risk. It is contraindicated in pregnancy, liver disease, and prostate or breast cancer.

Oxandrolone (Anavar) potentiates oral anticoagulants such as warfarin, and the labeling directs that anticoagulant doses be reduced and INR monitored closely to avoid bleeding. It can enhance the glucose-lowering effect of insulin and oral antidiabetic agents, so those doses may need adjustment. Oxandrolone is intrinsically hepatotoxic and can cause cholestatic injury and peliosis, so combining it with other hepatotoxic agents raises liver risk. Concurrent adrenocorticosteroids or ACTH can increase fluid retention and edema. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Anavar is the original brand name for oxandrolone, a synthetic derivative of dihydrotestosterone first synthesized around 1962 by Raphael Pappo and Christopher J. Jung at Searle Laboratories and introduced for medical use in 1964. Its distinctive 2-oxa A-ring modification was designed to maximize anabolic activity while minimizing androgenic effects, and it was prescribed for involuntary weight loss, burn recovery and bone-density loss. Searle discontinued Anavar in 1989 amid scrutiny of anabolic-steroid abuse by bodybuilders, and the drug nearly vanished from the market. It reappeared in 1995 when Bio-Technology General Corp relaunched oxandrolone under the brand Oxandrin, while the Anavar name lived on in bodybuilding and grey-market circles.